He sits on several advisory boards in companies involved in urologic technology development. He has been influential in the ergonomics of robotic technology. He has been active in the development of
optical coherence tomography and its application to urologic imaging.
Also active in the Laboratory of Urologic Oncology, Scherr has been instrumental in defining the hormonal regulation of bladder cancer and is currently developing a novel class of compounds that utilize the innate
immune system to fight urologic tumors. He is working on the development of a non-invasive means to assess human tissue at the microscopic level. To this end, he has patented and developed the concept of “multiphoton endoscopy” which utilizes high speed laser energy to create high quality microscopic images of human tissue. This breakthrough has vast applications in
cystoscopy,
colonoscopy and
bronchoscopy.
William Beaumont Medical Research Honor Society First Prize for Best Original Medical Essay, The William Shafirt Award, The George Washington University School of Medicine. “A crisis of unknown proportion: An empirical analysis of the American medical malpractice system.” 1994
First Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, “BCL-2 and P53 expression in clinically localized prostate cancer as predictive markers for the response to external beam radiotherapy.” 1998
First Prize for Clinical Investigation, Society of University Urology Residents, Annual Chief Resident Meeting, Marietta, Georgia. “Anti-androgen therapy for prostate cancer and the prevention of osteoporosis: The role of DES.” 2000
Second Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, “Collagen Type I Crosslinked N-Telopeptide as a urinary marker for osteoporosis in prostate cancer: The role of Diethylstilbesterol (DES).” 2000
Pfizer, Scholars in Urology Award, Awarded for advancing the scientific and clinical field of urology. 2000
Ferdinand C. Valentine Fellowship for Research in Urology. The
New York Academy of Medicine. 2001–2002. Syndecan-1 expression in prostate cancer and the role of p27 in primary prostate epithelial cell transformation.
Raman, JD; Scherr, DS (2007). "Management of patients with upper urinary tract transitional cell carcinoma". Nature Clinical Practice Urology. 4 (8): 432–43.
doi:
10.1038/ncpuro0875.
PMID17673914.
S2CID21351473.
Wang, GJ; Barocas, DA; Raman, JD; Scherr, DS (2008). "Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy". BJU International. 101 (1): 89–93.
doi:
10.1111/j.1464-410X.2007.07212.x.
PMID17888044.
S2CID10233606.
Liu, H; Schwartz, MJ; Hwang, DH; Scherr, DS (2008). "Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma". BJU International. 101 (7): 894–901.
doi:
10.1111/j.1464-410X.2008.07459.x.
PMID18241249.
S2CID205538510.
Barocas, DA; Rabbani, F; Scherr, DS; Vaughan Ed, ED (2006). "A population-based study of renal cell carcinoma and prostate cancer in the same patients". BJU International. 97 (1): 33–6.
doi:
10.1111/j.1464-410X.2005.05880.x.
PMID16336324.
S2CID10616104.
Barocas, DA; Rohan, SM; Kao, J; Gurevich, RD; Del Pizzo, JJ; Vaughan Ed, Jr; Akhtar, M; Chen, YT; Scherr, DS (2006). "Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis". The Journal of Urology. 176 (5): 1957–62.
doi:
10.1016/j.juro.2006.07.038.
PMID17070218.
Shelton, JB; Barocas, DA; Conway, F; Hart, K; Nelson, K; Richstone, L; Gonzalez, RR; Raman, JD; Scherr, DS (2005). "Prostate-specific antigen screening in a high-risk population: lessons from the community and how they relate to large-scale population-based studies". Urology. 65 (5): 931–6.
doi:
10.1016/j.urology.2004.11.047.
PMID15882726.
Boorjian, S; Ng, C; Munver, R; Palese, MA; Vaughan Ed, Jr; Sosa, RE; Del Pizzo, JJ; Scherr, DS (2005). "Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma". Urology. 66 (2): 283–7.
doi:
10.1016/j.urology.2005.02.022.
PMID16098357.
Pittsjr, W; Scherr, D (2005). "Unified theory of prostate cancer: the role of steroid 5 alpha reductase and steroid aromatase". Urology. 66 (3): 11–12.
doi:
10.1016/j.urology.2005.06.039.
Barocas, DA; Kawamoto, H; Dreizin, DF; Howard, ME; Choi, J; Pitts, WR; You, X; Tickoo, SK; et al. (2005). "Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome". Urology. 66 (5): 1134–9.
doi:
10.1016/j.urology.2005.06.079.
PMID16286153.
Scherr, D; Swindle, PW; Scardino, PT; National Comprehensive Cancer Network (2003). "National Comprehensive Cancer Network guidelines for the management of prostate cancer". Urology. 61 (2 Suppl 1): 14–24.
doi:
10.1016/S0090-4295(02)02395-6.
PMID12667883.
Scherr, Douglas S.; Ng, C; Munver, R; Sosa, RE; Vaughan Jr, ED; Del Pizzo, J (2003). "Practice patterns among urologic surgeons treating localized renal cell carcinoma in the laparoscopic age: technology versus oncology". Urology. 62 (6): 1007–11.
doi:
10.1016/S0090-4295(03)00773-8.
PMID14665345.
Scherr, DS; Pitts Wr, Jr (2003). "The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer". The Journal of Urology. 170 (5): 1703–8.
doi:
10.1097/01.ju.0000077558.48257.3d.
PMID14532759.
Knudsen, Beatrice S; Gmyrek, GA; Inra, J; Scherr, DS; Vaughan, ED; Nanus, DM; Kattan, MW; Gerald, WL; Vande Woude, GF (2002). "High expression of the Met receptor in prostate cancer metastasis to bone☆". Urology. 60 (6): 1113–7.
doi:
10.1016/S0090-4295(02)01954-4.
PMID12475693.
Scherr, D; Pittsjr, WR; Vaughanjr, ED (2002). "Diethylstilbesterol Revisited: Androgen Deprivation, Osteoporosis and Prostate Cancer". The Journal of Urology. 167 (2 Pt 1): 535–8.
doi:
10.1016/S0022-5347(01)69080-3.
PMID11792913.
Scherr, DS; Eastham, J; Ohori, M; Scardino, PT (2002). "Prostate biopsy techniques and indications: when, where, and how?". Seminars in Urologic Oncology. 20 (1): 18–31.
doi:
10.1053/suro.2002.30395.
PMID11828354.
Chen, A; Scherr, D; Eid, JF (2000). "Renal Transplantation After in Vivo Excision of an Angiomyolipoma from a Living Unrelated Kidney Donor". The Journal of Urology. 163 (6): 1859.
doi:
10.1016/S0022-5347(05)67561-1.
PMID10799200.
Scherr, DS; Vaughan Ed, Jr; Wei, J; Chung, M; Felsen, D; Allbright, R; Knudsen, BS (1999). "BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy". The Journal of Urology. 162 (1): 12–6, discussion 16–7.
doi:
10.1097/00005392-199907000-00003.
PMID10379729.
Scherr, D; Goldstein, M (1999). "Comparison of bilateral versus unilateral varicocelectomy in men with palpable bilateral varicoceles". The Journal of Urology. 162 (1): 85–8.
doi:
10.1097/00005392-199907000-00021.
PMID10379746.
He sits on several advisory boards in companies involved in urologic technology development. He has been influential in the ergonomics of robotic technology. He has been active in the development of
optical coherence tomography and its application to urologic imaging.
Also active in the Laboratory of Urologic Oncology, Scherr has been instrumental in defining the hormonal regulation of bladder cancer and is currently developing a novel class of compounds that utilize the innate
immune system to fight urologic tumors. He is working on the development of a non-invasive means to assess human tissue at the microscopic level. To this end, he has patented and developed the concept of “multiphoton endoscopy” which utilizes high speed laser energy to create high quality microscopic images of human tissue. This breakthrough has vast applications in
cystoscopy,
colonoscopy and
bronchoscopy.
William Beaumont Medical Research Honor Society First Prize for Best Original Medical Essay, The William Shafirt Award, The George Washington University School of Medicine. “A crisis of unknown proportion: An empirical analysis of the American medical malpractice system.” 1994
First Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, “BCL-2 and P53 expression in clinically localized prostate cancer as predictive markers for the response to external beam radiotherapy.” 1998
First Prize for Clinical Investigation, Society of University Urology Residents, Annual Chief Resident Meeting, Marietta, Georgia. “Anti-androgen therapy for prostate cancer and the prevention of osteoporosis: The role of DES.” 2000
Second Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, “Collagen Type I Crosslinked N-Telopeptide as a urinary marker for osteoporosis in prostate cancer: The role of Diethylstilbesterol (DES).” 2000
Pfizer, Scholars in Urology Award, Awarded for advancing the scientific and clinical field of urology. 2000
Ferdinand C. Valentine Fellowship for Research in Urology. The
New York Academy of Medicine. 2001–2002. Syndecan-1 expression in prostate cancer and the role of p27 in primary prostate epithelial cell transformation.
Raman, JD; Scherr, DS (2007). "Management of patients with upper urinary tract transitional cell carcinoma". Nature Clinical Practice Urology. 4 (8): 432–43.
doi:
10.1038/ncpuro0875.
PMID17673914.
S2CID21351473.
Wang, GJ; Barocas, DA; Raman, JD; Scherr, DS (2008). "Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy". BJU International. 101 (1): 89–93.
doi:
10.1111/j.1464-410X.2007.07212.x.
PMID17888044.
S2CID10233606.
Liu, H; Schwartz, MJ; Hwang, DH; Scherr, DS (2008). "Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma". BJU International. 101 (7): 894–901.
doi:
10.1111/j.1464-410X.2008.07459.x.
PMID18241249.
S2CID205538510.
Barocas, DA; Rabbani, F; Scherr, DS; Vaughan Ed, ED (2006). "A population-based study of renal cell carcinoma and prostate cancer in the same patients". BJU International. 97 (1): 33–6.
doi:
10.1111/j.1464-410X.2005.05880.x.
PMID16336324.
S2CID10616104.
Barocas, DA; Rohan, SM; Kao, J; Gurevich, RD; Del Pizzo, JJ; Vaughan Ed, Jr; Akhtar, M; Chen, YT; Scherr, DS (2006). "Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis". The Journal of Urology. 176 (5): 1957–62.
doi:
10.1016/j.juro.2006.07.038.
PMID17070218.
Shelton, JB; Barocas, DA; Conway, F; Hart, K; Nelson, K; Richstone, L; Gonzalez, RR; Raman, JD; Scherr, DS (2005). "Prostate-specific antigen screening in a high-risk population: lessons from the community and how they relate to large-scale population-based studies". Urology. 65 (5): 931–6.
doi:
10.1016/j.urology.2004.11.047.
PMID15882726.
Boorjian, S; Ng, C; Munver, R; Palese, MA; Vaughan Ed, Jr; Sosa, RE; Del Pizzo, JJ; Scherr, DS (2005). "Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma". Urology. 66 (2): 283–7.
doi:
10.1016/j.urology.2005.02.022.
PMID16098357.
Pittsjr, W; Scherr, D (2005). "Unified theory of prostate cancer: the role of steroid 5 alpha reductase and steroid aromatase". Urology. 66 (3): 11–12.
doi:
10.1016/j.urology.2005.06.039.
Barocas, DA; Kawamoto, H; Dreizin, DF; Howard, ME; Choi, J; Pitts, WR; You, X; Tickoo, SK; et al. (2005). "Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome". Urology. 66 (5): 1134–9.
doi:
10.1016/j.urology.2005.06.079.
PMID16286153.
Scherr, D; Swindle, PW; Scardino, PT; National Comprehensive Cancer Network (2003). "National Comprehensive Cancer Network guidelines for the management of prostate cancer". Urology. 61 (2 Suppl 1): 14–24.
doi:
10.1016/S0090-4295(02)02395-6.
PMID12667883.
Scherr, Douglas S.; Ng, C; Munver, R; Sosa, RE; Vaughan Jr, ED; Del Pizzo, J (2003). "Practice patterns among urologic surgeons treating localized renal cell carcinoma in the laparoscopic age: technology versus oncology". Urology. 62 (6): 1007–11.
doi:
10.1016/S0090-4295(03)00773-8.
PMID14665345.
Scherr, DS; Pitts Wr, Jr (2003). "The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer". The Journal of Urology. 170 (5): 1703–8.
doi:
10.1097/01.ju.0000077558.48257.3d.
PMID14532759.
Knudsen, Beatrice S; Gmyrek, GA; Inra, J; Scherr, DS; Vaughan, ED; Nanus, DM; Kattan, MW; Gerald, WL; Vande Woude, GF (2002). "High expression of the Met receptor in prostate cancer metastasis to bone☆". Urology. 60 (6): 1113–7.
doi:
10.1016/S0090-4295(02)01954-4.
PMID12475693.
Scherr, D; Pittsjr, WR; Vaughanjr, ED (2002). "Diethylstilbesterol Revisited: Androgen Deprivation, Osteoporosis and Prostate Cancer". The Journal of Urology. 167 (2 Pt 1): 535–8.
doi:
10.1016/S0022-5347(01)69080-3.
PMID11792913.
Scherr, DS; Eastham, J; Ohori, M; Scardino, PT (2002). "Prostate biopsy techniques and indications: when, where, and how?". Seminars in Urologic Oncology. 20 (1): 18–31.
doi:
10.1053/suro.2002.30395.
PMID11828354.
Chen, A; Scherr, D; Eid, JF (2000). "Renal Transplantation After in Vivo Excision of an Angiomyolipoma from a Living Unrelated Kidney Donor". The Journal of Urology. 163 (6): 1859.
doi:
10.1016/S0022-5347(05)67561-1.
PMID10799200.
Scherr, DS; Vaughan Ed, Jr; Wei, J; Chung, M; Felsen, D; Allbright, R; Knudsen, BS (1999). "BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy". The Journal of Urology. 162 (1): 12–6, discussion 16–7.
doi:
10.1097/00005392-199907000-00003.
PMID10379729.
Scherr, D; Goldstein, M (1999). "Comparison of bilateral versus unilateral varicocelectomy in men with palpable bilateral varicoceles". The Journal of Urology. 162 (1): 85–8.
doi:
10.1097/00005392-199907000-00021.
PMID10379746.